AstraZeneca reaffirms COVID-19 vaccine data after experts question results from manufacturing error; shown to be 70% effective

Data on a candidate COVID-19 vaccine made by AstraZeneca and Oxford University are strong enough to present to regulators in the U.K., Europe and elsewhere around the world, the collaborators said Tuesday, but they don’t expect approval from the U.S. without more data from American volunteers. The team presented their data Tuesday in the medical journal, The Lancet, the first late-stage trial information to be published under peer review, with careful independent analysis.